Article
Oncology
Amarinder Singh Thind, Bruce Ashford, Dario Strbenac, Jenny Mitchell, Jenny Lee, Simon A. A. Mueller, Elahe Minaei, Jay R. R. Perry, Sydney Ch'ng, N. Gopalakrishna Iyer, Jonathan R. R. Clark, Ruta Gupta, Marie Ranson
Summary: Metastatic cutaneous squamous cell carcinoma (CSCC) has a complex genomic landscape. This study provides a comprehensive analysis of the genomic components of metastatic CSCC and identifies potential non-coding biomarkers and novel driver genes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Cara Dauch, Sharon Shim, Matthew Wyatt Cole, Nijole C. Pollock, Abigail J. Beer, Johnny Ramroop, Victoria Klee, Dawn C. Allain, Reena Shakya, Sue E. Knoblaugh, Jesse Kulewsky, Amanda Ewart Toland
Summary: Loss of KMT2D may promote more aggressive and invasive behaviors in cSCC, suggesting potential targets for cancer therapies.
AMERICAN JOURNAL OF CANCER RESEARCH
(2022)
Article
Cell Biology
Guorong Yan, Liang Li, Sibo Zhu, Yuhao Wu, Yeqiang Liu, Lude Zhu, Zijun Zhao, Fei Wu, Ning Jia, Caihe Liao, Long Jiang, Qingyu Zeng, Peiru Wang, Lei Shi, Zhe Zheng, Shan Fang, Guolong Zhang, Yichen Tang, Xiuli Wang
Summary: This study identified the molecular patterns of cutaneous squamous cell carcinoma (cSCC) at the single-cell level using single-cell transcriptome analysis. The results showed significant differences in gene expression and chromosomal copy number variation between cSCC cells and normal keratinocytes. The upregulation of S100A9 and FABP5 in cSCC cells was found to promote cell proliferation and migration through the NF-kappa B pathway.
CELL DEATH & DISEASE
(2022)
Article
Dermatology
Neha Gupta, Rachel E. Weitzman, Fadi Murad, Shlomo A. Koyfman, Timothy D. Smile, Michael S. Chang, Jacqueline M. Maher, Chrysalyne D. Schmults, Allison T. Vidimos, Emily S. Ruiz
Summary: This study aimed to determine the risk factors associated with poor outcomes in BWH T2a tumors. The presence of certain criteria was found to be predictive of poor outcomes, with an 8% incidence rate in these tumors.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Oncology
Timothy Budden, Caroline Gaudy-Marqueste, Sarah Craig, Yuan Hu, Charles H. Earnshaw, Shilpa Gurung, Amelle Ra, Victoria Akhras, Patrick Shenjere, Ruth Green, Lynne Jamieson, John Lear, Luisa Motta, Carlos Caulin, Deemesh Oudit, Simon J. Furney, Amaya Viros
Summary: This study demonstrates that cSCC is more aggressive in men, while immunocompetent women develop mild cSCC later in life. The research also shows that female immunity offers greater protection than male immunity against cSCC.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Hui Wang, Hong Li, Qingtao Yan, Sumei Gao, Jianfang Gao, Zhenhua Wang, Yi Sun
Summary: Serum MMP-13 levels are significantly higher in patients with cSCC compared to healthy controls, particularly in those with invasive cSCC. Surgical removal of cSCC results in a significant decrease in serum MMP-13 levels. Serum MMP-13 can predict the invasiveness of cSCC and lymph node involvement with high sensitivity and specificity.
Article
Medicine, Research & Experimental
Craig P. Mooney, Kan Gao, Jonathan R. Clark, Ruta Gupta, Kerwin Shannon, Carsten E. Palme, Ardalan Ebrahimi, Sydney Ch'ng, Tsu-Hui (Hubert) Low
Summary: Soft tissue metastases (STM) in head and neck cutaneous squamous cell carcinoma (HNcSCC) are non-nodal based metastases to the parotid and cervical soft tissues of the head and neck. This study found that the presence of STM is associated with poor prognosis in HNcSCC patients, with age and number of STM deposits being independent predictors of worse survival.
Review
Medicine, General & Internal
Che-Yuan Hsu, Teruki Yanagi, Hideyuki Ujiie
Summary: TRIM proteins, including TRIM29, are essential in a variety of cell processes and have been linked to functions such as DNA binding, carcinogenesis, DNA damage signaling, and radioresistance. In particular, TRIM29 plays a significant role in regulating keratin distribution and is involved in cutaneous squamous cell carcinoma.
FRONTIERS IN MEDICINE
(2021)
Review
Oncology
Flora Yan, Brittny N. Tillman, Rajiv I. Nijhawan, Divya Srivastava, David J. Sher, Vladimir Avkshtol, Jade Homsi, Justin A. Bishop, Erin M. Wynings, Rebecca Lee, Larry L. Myers, Andrew T. Day
Summary: The current state of high-risk head and neck cutaneous squamous cell carcinoma (HNcSCC) is poorly characterized due to the rapidly evolving nature of the field. Clinical and pathologic risk factors for adverse outcomes are nuanced, leading to challenges in treatment and staging systems. Population-based registries tracking updated, nuanced risk factors and outcomes are needed to guide the development of improved staging systems, along with more randomized controlled trials to evaluate treatment methods.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Gink N. Yang, Xanthe L. Strudwick, Claudine S. Bonder, Zlatko Kopecki, Allison J. Cowin
Summary: Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer in Caucasian populations, with aggressive metastatic forms having poor patient outcomes. Studies have shown that the actin-remodeling protein Flightless (Flii) plays a role in regulating cSCC proliferation and tumor progression through the Wnt/β-catenin signaling pathway. Knockdown of Flii led to decreased β-catenin and a reduction in the downstream effector protein SOX9, indicating its potential as a target for aggressive metastatic cSCC treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Carrick Burns, Shelby Kubicki, Quoc-Bao Nguyen, Nader Aboul-Fettouh, Kelly M. Wilmas, Olivia M. Chen, Hung Quoc Doan, Sirunya Silapunt, Michael R. Migden
Summary: Cutaneous squamous cell carcinoma (cSCC) is a prevalent and morbid cancer, and recent developments in risk stratification and treatment options, such as immune checkpoint inhibitors, have improved outcomes for patients with locally advanced and metastatic disease. Ongoing clinical trials continue to advance the field and offer hope for better management of cSCC in the future.
Review
Oncology
Clio Dessinioti, Alexander J. Stratigos
Summary: This review discusses the characteristics and management of high-risk cutaneous squamous cell carcinoma (cSCC). Factors to consider regarding the follow-up schedule for patients diagnosed with high-risk cSCC include the risk and possible time of occurrence of metastasis.
Review
Biochemistry & Molecular Biology
Matthew L. Hedberg, Corbett T. Berry, Ata S. Moshiri, Yan Xiang, Christopher J. Yeh, Cem Attilasoy, Brian C. Capell, John T. Seykora
Summary: Non-melanoma skin cancers, primarily basal cell carcinomas and squamous cell carcinomas, are the most common form of cancer in the US. The increasing incidence of squamous cell carcinomas leads to significant morbidity and rising treatment costs, exceeding one billion dollars annually. Research on the molecular basis and development of squamous cell carcinomas aims to provide new insights into pathogenesis and drive the development of cost-effective and low morbidity therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Moran Amit, Chuan Liu, Jobran Mansour, Frederico O. Gleber-Netto, Samantha Tam, Erez N. Baruch, Mohamed Aashiq, Adel K. El-Naggar, Amy C. Moreno, David I. Rosenthal, Bonnie S. Glisson, Renata Ferrarotto, Michael K. Wong, Kenneth Tsai, Elsa R. Flores, Michael R. Migden, Deborah A. Silverman, Goujun Li, Anshu Khanna, Ryan P. Goepfert, Priyadharsini Nagarajan, Randal S. Weber, Jeffrey N. Myers, Neil D. Gross
Summary: The study showed that elective neck dissection (END) did not improve survival rates for patients with cutaneous squamous cell carcinoma (cSCC) of the head and neck and no evidence of regional metastasis. Further research is needed to clarify the role of END in patients with advanced disease.
Review
Medicine, General & Internal
Ashley Wysong
Summary: Squamous-cell carcinoma is a common type of cancer in humans, with most cases being localized and treatable, but a small percentage of cases that recur or spread can be fatal. Immunocompromised patients are at particularly high risk.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Letter
Dermatology
A. Ji-Xu, J. Dinnes, R. N. Matin
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Article
Dermatology
Zeeshaan-Ul Hasan, Ikhlaaq Ahmed, Rubeta N. Matin, Victoria Homer, John T. Lear, Ferina Ismail, Tristan Whitmarsh, Adele C. Green, Jason Thomson, Alan Milligan, Sarah Hogan, Vanessa Van-de-Velde, Liza Mitchell-Worsford, Jonathan Kentley, Claire Gaunt, Yolande Jefferson-Hulme, Sarah J. Bowden, Piers Gaunt, Keith Wheatley, Charlotte M. Proby, Catherine A. Harwood
Summary: This study aimed to evaluate the feasibility, activity, and evaluation outcomes of topical chemoprevention of cSCC in OTRs, and the results support further investigation of 5-FU-based treatments in future phase III trials.
BRITISH JOURNAL OF DERMATOLOGY
(2022)
Article
Dermatology
Joshua Philip Totty, Rubeta N. Matin, Aaron Wernham, Ruby Ray, Emma Thomas-Jones, Rachel Angharad Abbott
Summary: Skin cancer is the most common malignancy in the UK, and a significant number of lesions are ulcerated at the time of excision. Ulceration has been linked to increased risk of surgical site infection, and studies have shown varying rates of infection. However, there are no specific guidelines for antibiotic prophylaxis in these cases. A survey of clinicians who regularly perform skin lesion excisions revealed significant variability in their practice, indicating a need for a well-designed clinical trial to guide future treatment approaches.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Letter
Dermatology
W. Ye, M. Kim, B. P. Fairfax, N. Coupe, M. J. Payne, R. N. Matin
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Article
Dermatology
R. A. Abbott, A. Cordaro, B. Lloyd, R. Cannings-John, M. Wootton, N. Kirby, T. Pickles, A. McQueen, M. Westmoreland, S. Ziaj, A. Martin-Clavijo, A. Wernham, R. Matin, E. Thomas-Jones
Summary: This study investigated the proportion of surgical site infection (SSI) after excision of ulcerated skin cancer and found a high rate of SSI. The results showed that the Wound Healing Questionnaire was acceptable to patients, but further evaluation is needed to ensure validity.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Article
Medicine, General & Internal
Peter W. Horby, Guilherme Pessoa-Amorim, Natalie Staplin, Jonathan R. Emberson, Mark Campbell, Enti Spata, Leon Peto, Nigel J. Brunskill, Simon Tiberi, Victor Chew, Thomas Brown, Hasan Tahir, Beate Ebert, David Chadwick, Tony Whitehouse, Rahuldeb Sarkar, Clive Graham, J. Kenneth Baillie, Buddha Basnyat, Maya H. Buch, Lucy C. Chappell, Jeremy Day, Saul N. Faust, Raph L. Hamers, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, Martin J. Landray
Summary: In patients hospitalized with COVID-19, aspirin was not associated with reductions in 28-day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days.
Article
Oncology
Marius Tham, Hans-Juergen Stark, Anna Jauch, Catherine Harwood, Elizabeth Pavez Lorie, Petra Boukamp
Summary: The BRAF inhibitor vemurafenib can activate the MEK-ERK signaling pathway in both keratinocytes and fibroblasts, leading to cutaneous adverse events. The effects of vemurafenib on skin keratinocytes depend on their genetic background and can result in tumor progression.
FRONTIERS IN ONCOLOGY
(2022)
Article
Health Care Sciences & Services
Chidiebere Nwolise, Pippa Corrie, Ray Fitzpatrick, Avinash Gupta, Crispin Jenkinson, Mark Middleton, Rubeta Matin
Summary: This study highlights the substantial burden faced by patients with advanced melanoma in a clinical trial and the factors that may lessen or worsen this burden. Considering these burdens can reduce the burden experienced by research participants during trial design and execution.
Review
Oncology
Thomas J. Carter, Christina George, Catherine Harwood, Paul Nathan
Summary: This article provides a framework for the investigation and multidisciplinary management of pregnancy associated melanoma (PAM) based on existing literature.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Oliver Cassell, Catherine Harwood, Melanie Hovey, Miranda Payne
Summary: This study investigates the current management pathways for patients with resected stage III melanoma in the UK and explores the expected changes with the routine availability of systemic adjuvant melanoma treatments. The findings suggest that the introduction of adjuvant therapy will have significant implications for the commissioning, organization, and delivery of melanoma services.
EUROPEAN JOURNAL OF CANCER CARE
(2022)
Article
Genetics & Heredity
Chinedu A. Anene, Emma Taggart, Catherine A. Harwood, Daniel J. Pennington, Jun Wang
Summary: This study introduces an R package called Decosus, which integrates seven methods and gene expression profiles for deconvoluting cell types. Benchmark analysis and ground-truth measurements show that integrated estimates have stable performances across datasets and can be applied to skin samples in different settings.
FRONTIERS IN GENETICS
(2022)
Article
Dermatology
Soha S. Tawfik, Bjorn R. Thomas, David P. Kelsell, Jonathan Grigg, Edel A. O'Toole
Summary: This study examines the impact of atopic eczema on the quality of life of Bangladeshi children and young adults, and finds that factors such as disease severity, distribution, family dynamics, and socioeconomic status influence the quality of life of patients.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Biographical-Item
Cell Biology
Klaus Unsicker, Brigitte M. Jockusch, David P. Kelsell
CELL AND TISSUE RESEARCH
(2022)
Article
Medicine, General & Internal
Peter W. Horby, Marion Mafham, Leon Peto, Mark Campbell, Guilherme Pessoa-Amorim, Enti Spata, Natalie Staplin, Jonathan R. Emberson, Benjamin Prudon, Paul Hine, Thomas Brown, Christopher A. Green, Rahuldeb Sarkar, Purav Desai, Bryan Yates, Tom Bewick, Simon Tiberi, Tim Felton, J. Kenneth Baillie, Maya H. Bitch, Lucy C. Chappell, Saul N. Faust, Thomas Jaki, Katie Jeffery, Edmund Juszczak, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, David M. Weinreich, Richard Haynes, Martin J. Landray
Summary: This study evaluated the efficacy and safety of the combination therapy of casirivimab and imdevimab in patients hospitalized with COVID-19. The results showed that this combination therapy reduced the 28-day mortality rate in patients without detectable antibodies to SARS-CoV-2 infection at baseline, but not in those with detectable antibodies.
Article
Rheumatology
Joanna Kefas, Catherine Harwood, Myles J. Lewis, Peter Szlosarek
Summary: This case report presents a rare complication of digital ischemia in a patient with malignant pleural mesothelioma following PD-1 and CTLA-4 blockade therapy. The case highlights the importance of early detection, intervention, and a multispecialty approach in managing such complications.